HURA: TuHURA Biosciences, Inc. Price/Earnings to Growth Multiple

Strategic partnerships with oncology centers to develop vaccines are driving momentum, as illustrated by the P/E to G growth valuation metric for TuHURA Biosciences, Inc. (HURA). The value 0.00 reflects the current level of this metric. This paves the way for high-margin global sales of innovations, provided there is effective collaboration with contract research organizations to mitigate operational risks during drug testing.

Price/Earnings to Growth Ratio: TuHURA Biosciences Inc. (HURA) for 07/04/2022 - 11/15/2026

TuHURA Biosciences, Inc. (HURA) - metric breakdowns and financial figures

- share price and consensus valuation forecast:

Price Performance Chart TuHURA Biosciences|HURA - Analyst Consensus Forecast

- market capitalization information:

Market Valuation TuHURA Biosciences, Inc.|HURA - Real Price to Acquire Entire Company

- book value of equity indicators:

Book Value per Share TuHURA Biosciences|HURA - Company Book Value|Market Value to Book Value tuhurabio.com|HURA - Company Total Assets

- business debt structure and liquidity details:

- company profitability and valuation multiples indicators:

HURA - Company Net Income|Expected Net Income TuHURA Biosciences, Inc.|HURA - P/E Multiple|Forward P/E Multiple TuHURA|HURA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation TuHURA Biosciences, Inc.|HURA - Operating profit EBITDA|Earnings per share for the last twelve months TuHURA Biosciences|HURA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months tuhurabio.com|HURA - Earnings per share growth in current year|Expected net earnings per share growth next year TuHURA Biosciences, Inc.

- total revenue and sales volume data:

HURA - Company Revenue|Company Future Sales TuHURA Biosciences|HURA - P/S Multiple|Forward Price-to-Revenue Multiple TuHURA Biosciences, Inc.|HURA - Sales Growth YoY (TTM)

Summary company analytics:HURA TuHURA

The metric is calculated by dividing the P/E ratio by the earnings growth rate, determining the fair value of the asset relative to its expansion. For TuHURA Biosciences, Inc. (HURA), whose operations are limited to safe laboratory research in onco-immunology, the PEG ratio chart allows for an assessment of how closely the market price aligns with drug development potential, identifying the company as undervalued when values fall below one.

Competing companies